MAPK1 and cancer: It will be interesting to assess whether this targeting strategy also overrides the MEK inhibitor resistance due to the recently described ERK2 mutations in human cancer, ERK2(E322K) and ERK2(D321N) located within the highly conserved common docking (CD) region close to the proposed binding site of EDI/JOLU2264,65.